Radiopharmacies Market Report 2026

Radiopharmacies Market Overview

• Radiopharmacies market size has reached to $10.3 billion in 2025 • Expected to grow to $15.26 billion in 2030 at a compound annual growth rate (CAGR) of 8.2% • Growth Driver: The Rising Prevalence Of Cancer And Chronic Diseases Is Fueling The Growth Of The Market Due To Increasing Patient Demand For Diagnostic And Therapeutic Radiopharmaceuticals • Market Trend: Advancing Healthcare With Innovative Production Technologies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Radiopharmacies Market?

Radiopharmacies are specialized facilities that prepare, compound, and dispense radioactive materials for medical and research applications. They ensure the safe handling, accurate dosing, and quality control of radiopharmaceuticals used in diagnostic imaging and therapy. These operations follow strict regulatory and safety standards to protect personnel and maintain the integrity of the radioactive products. The main product types of radiopharmacies include diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. Diagnostic radiopharmaceuticals refer to radioactive compounds used in imaging procedures to detect, diagnose, and monitor diseases within the body. The different service types include radiopharmaceutical compounding, dose preparation, nuclear medicine drug dispensing, quality control and assurance, radiation safety management, logistics and delivery, inventory management, regulatory compliance support, and consulting and training services and the various radioisotope types include technetium-based radiopharmaceuticals, fluorine-based radiopharmaceuticals, iodine-based radiopharmaceuticals, gallium-based radiopharmaceuticals, lutetium-based radiopharmaceuticals, and other radioisotope types. The key applications of oncology, cardiology, neurology, endocrinology, and other applications, while the end-use includes hospitals, diagnostic imaging centers, research institutes, and specialty clinics.

What Is The Radiopharmacies Market Growth Forecast?

The radiopharmacies market size is expected to see strong growth in the next few years.It will grow to $15.26 billion by 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing development of targeted radionuclide therapies, rising investment in PET and SPECT imaging technologies, growing expansion of personalized medicine applications, increasing establishment of centralized radiopharmacy networks, rising demand for advanced radiopharmaceutical logistics and cold chain solutions.Major trends in the forecast period include increasing demand for targeted radiopharmaceutical therapies in oncology, growing adoption of centralized radiopharmacy services for efficient dose preparation, rising focus on radiation safety and regulatory compliance in radiopharmacies, expansion of nuclear medicine applications in cardiology and neurology, increasing investment in advanced quality control and assurance systems for radiopharmaceutical handling.

Global Radiopharmacies Market Segmentation

1) By Product Type: Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals 2) By Service Type: Radiopharmaceutical Compounding, Dose Preparation, Nuclear Medicine Drug Dispensing, Quality Control And Assurance, Radiation Safety Management, Logistics And Delivery, Inventory Management, Regulatory Compliance Support, Consulting And Training Services 3) By Radioisotope Type: Technetium-Based Radiopharmaceuticals, Fluorine-Based Radiopharmaceuticals, Iodine-Based Radiopharmaceuticals, Gallium-Based Radiopharmaceuticals, Lutetium-Based Radiopharmaceuticals, Other Radioisotope Types 4) By Application: Oncology, Cardiology, Neurology, Endocrinology, Other Applications 5) By End User: Hospitals, Diagnostic Imaging Centers, Research Institutes, Specialty Clinics Subsegments: 1) By Diagnostic Radiopharmaceuticals: Single Photon Emission Computed Tomography Radiopharmaceuticals, Positron Emission Tomography Radiopharmaceuticals, Bone Imaging Radiopharmaceuticals, Cardiac Imaging Radiopharmaceuticals, Renal Imaging Radiopharmaceuticals 2) By Therapeutic Radiopharmaceuticals: Radioiodine Therapy Radiopharmaceuticals, Radiolabeled Antibody Therapy, Peptide Receptor Radionuclide Therapy, Bone Pain Palliation Radiopharmaceuticals, Liver Cancer Therapy Radiopharmaceuticals

What Is The Driver Of The Radiopharmacies Market?

The rising prevalence of cancer and chronic diseases are expected to propel the growth of the radiopharmacies industry going forward.Cancer and chronic diseases refer to long lasting health conditions, such as cancer, diabetes, heart disease, and respiratory illnesses, that require ongoing medical attention and can persist for months or years.The prevalence of cancer and chronic diseases is rising due to aging populations because as people grow older, their risk of developing long-term illnesses such as cancer, diabetes, and heart disease naturally increases.Radiopharmacies facilitate the diagnosis and treatment of cancer and chronic diseases by producing and supplying specialized radioactive drugs used in medical imaging and targeted therapies, enabling precise detection, monitoring, and therapy of these conditions.For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022.Therefore, the rising prevalence of cancer and chronic diseases is driving the growth of the radiopharmacies industry.

Key Players In The Global Radiopharmacies Market

Major companies operating in the radiopharmacies market are Cardinal Health Inc., Siemens Healthineers AG, GE HealthCare Technologies Inc., BWX Technologies Inc., Bracco Imaging S. p. A., Lantheus Holdings Inc., China Isotope & Radiation Corporation, Ion Beam Applications S. A. (IBA), Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen, PharmaLogic Holdings Corp., Shine Technologies LLC, NTP Radioisotopes SOC Ltd., NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, ARTBIO Inc., Isotopia Molecular Imaging Ltd., AdvanCell Isotopes Pty Ltd, Futurechem Co. Ltd., Jubilant Radiopharma Pvt. Ltd., Cyclotek (Aust) Pty Ltd., Radiomedix Inc., Iso‑Tex Diagnostics Inc., Nucleus RadioPharma Inc.

Global Radiopharmacies Market Trends and Insights

Major companies operating in the radiopharmacies market are focusing on developing innovative initiatives such as advanced radiopharmaceutical production facilities to enhance production efficiency and ensure a reliable supply of diagnostic and therapeutic radiopharmaceuticals. Advanced radiopharmaceutical production facilities are specialized centres that manufacture radioactive compounds for medical imaging and therapy with high precision and safety, helping ensure consistent quality, faster production, and reliable supply of diagnostic and therapeutic radiopharmaceuticals. For instance, in October 2024, PharmaLogic Holdings Corp., a US-based manufacturing company, opened a state-of-the-art radiopharmaceutical production facility in Los Angeles to enhance its capacity to supply critical imaging agents. The facility features automated synthesis modules, stringent quality control protocols, and scalable production lines, enabling consistent and high-purity radiotracer manufacturing. It supports the production of PET and SPECT imaging agents, reducing human error, minimizing contamination risks, and improving turnaround times compared to conventional laboratories.

What Are Latest Mergers And Acquisitions In The Radiopharmacies Market?

In January 2025, Telix Pharmaceuticals Limited, an Australia-based healthcare technology company, acquired RLS (USA) Inc. for an undisclosed amount. With this acquisition, Telix aims to establish an integrated radiopharmaceutical ecosystem, enhancing its ability to deliver novel therapeutic and diagnostic radiopharmaceuticals across the U. S., streamline its supply chain, accelerate clinical development programs, and expand patient access to innovative imaging and treatment solutions. RLS (USA) Inc. is a U. S. -based healthcare technology company that specializes in radiopharmacies.

Regional Insights

North America was the largest region in the radiopharmacies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Radiopharmacies Market?

The radiopharmacies market consists of revenues earned by entities by providing services such as preparation and compounding of radiopharmaceuticals, quality control testing, packaging and labeling of radioactive drugs, distribution to healthcare facilities, and regulatory compliance management. The market value includes the value of related goods sold by the service provider or included within the service offering. The radiopharmacies market also includes sales of radiotracers, radioisotopes, cold kits, radiolabeled monoclonal antibodies, and quality control reagents and testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

What is the Market Assessment and Strategic Outlook for the Radiopharmacies Industry?

The radiopharmacies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmacies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

What is the Market Assessment and Strategic Outlook for the Radiopharmacies Market Report 2026?

The radiopharmacies market research report is one of a series of new reports from The Business Research Company that provides radiopharmacies market statistics, including radiopharmacies industry global market size, regional shares, competitors with a radiopharmacies market share, detailed radiopharmacies market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmacies industry. This radiopharmacies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.